Patents by Inventor Maurice Zauderer

Maurice Zauderer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of PD-L1 Low Expression Status to Select Subjects for Cancer Immunotherapy
    Publication number: 20250052757
    Abstract: The disclosure relates to methods for treating cancer or selecting subjects for cancer treatment using low PD-L1 expression as a patient biomarker prior to treatment.
    Type: Application
    Filed: August 9, 2024
    Publication date: February 13, 2025
    Inventors: Elizabeth EVANS, Maurice ZAUDERER, Terry FISHER
  • USE OF SEMAPHORIN-4D ANTIBODIES IN COMBINATION WITH AN IMMUNE MODULATING THERAPY TO INHIBIT TUMOR GROWTH AND METASTASIS
    Publication number: 20250032609
    Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
    Type: Application
    Filed: July 18, 2024
    Publication date: January 30, 2025
    Applicant: Vaccinex, Inc.
    Inventors: Elizabeth E. Evans, Ernest S. Smith, Maurice Zauderer
  • HUMAN ANTI-SEMAPHORIN 4D ANTIBODY
    Publication number: 20240309091
    Abstract: Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
    Type: Application
    Filed: May 3, 2024
    Publication date: September 19, 2024
    Applicant: VACCINEX, INC.
    Inventors: Ernest S. SMITH, Angelica CORNELISON, Maria SCRIVENS, Mark PARIS, Maurice ZAUDERER
  • Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis
    Patent number: 12070500
    Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: August 27, 2024
    Assignee: VACCINEX, INC.
    Inventors: Elizabeth E. Evans, Ernest S. Smith, Maurice Zauderer
  • Human anti-semaphorin 4D antibody
    Patent number: 12006365
    Abstract: Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: June 11, 2024
    Assignee: VACCINEX, INC.
    Inventors: Ernest S. Smith, Angelica Cornelison, Maria Scrivens, Mark Paris, Maurice Zauderer
  • COMBINATION THERAPY WITH SEMAPHORIN-4D BLOCKADE AND HTT-LOWERING AGENT FOR TREATMENT OF HUNTINGTON'S DISEASE
    Publication number: 20230331863
    Abstract: Disclosed are combination therapies and methods for the treatment of Huntington's disease comprising the administration of a combination of a SEMA4D binding molecule and an HTT-lowering agent.
    Type: Application
    Filed: February 13, 2023
    Publication date: October 19, 2023
    Inventors: Elizabeth Evans, Terrence Fisher, Amber Southwell, Yuanyun Xie, Maurice Zauderer
  • PREDICTIVE OUTCOME PROFILING FOR USE OF AN ANTI-SEMAPHORIN-4D BINDING MOLECULE TO TREAT NEURODEGENERATIVE DISORDERS
    Publication number: 20230101618
    Abstract: Provided herein are methods for selecting subjects having a neurodegenerative disorder for treatment with an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D), method for predicting the treatment outcome of subjects having a neurodegenerative disorder that are treated with an isolated binding molecule which specifically binds to SEMA4D and methods for treating subjects having a neurodegenerative disorder with an isolated binding molecule which specifically binds to SEMA4D.
    Type: Application
    Filed: September 23, 2022
    Publication date: March 30, 2023
    Inventors: Maurice Zauderer, Elizabeth Evans, Terrence Fisher
  • Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
    Patent number: 11597765
    Abstract: Provided herein are methods for alleviating symptoms in a subject having Rett syndrome, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: March 7, 2023
    Assignees: VACCINEX, INC., The Sydney Children's Hospital Network
    Inventors: Yilin Mao, Wendy Gold, Elizabeth E. Evans, Maurice Zauderer
  • Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent
    Patent number: 11572408
    Abstract: This disclosure provides a method for inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising administering to the subject a combination therapy comprising an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an epigenetic modulating agent, e.g., a histone deacetylase (HDAC) inhibitor (HDACi) a DNA methyltransferase (DNMT) inhibitor (DNMTi), or any combination thereof. The disclosure further provides a pharmaceutical composition comprising the combination therapy.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: February 7, 2023
    Assignee: Vaccinex, Inc.
    Inventors: Elizabeth Evans, Ernest Smith, Maurice Zauderer
  • Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
    Patent number: 11534488
    Abstract: Provided herein are methods for decreasing blood-brain barrier permeability in a subject with a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: December 27, 2022
    Assignee: VACCINEX, INC.
    Inventors: Ernest S. Smith, Maurice Zauderer
  • HUMAN ANTI-SEMAPHORIN 4D ANTIBODY
    Publication number: 20220356249
    Abstract: Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
    Type: Application
    Filed: July 19, 2022
    Publication date: November 10, 2022
    Inventors: Ernest S. SMITH, Angelica CORNELISON, Maria SCRIVENS, Mark PARIS, Maurice ZAUDERER
  • Human anti-semaphorin 4D antibody
    Patent number: 11427634
    Abstract: Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: August 30, 2022
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Angelica Cornelison, Maria G. M. Scrivens, Mark Paris, Maurice Zauderer
  • USE OF SEMAPHORIN-4D BINDING MOLECULES FOR THE TREATMENT OF RETT SYNDROME
    Publication number: 20210403559
    Abstract: Provided herein are methods for alleviating symptoms in a subject having Rett syndrome, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).
    Type: Application
    Filed: June 21, 2021
    Publication date: December 30, 2021
    Inventors: Yilin Mao, Wendy Gold, Elizabeth E. Evans, Maurice Zauderer
  • USE OF SEMAPHORIN-4D INHIBITORY MOLECULES WITH AN IMMUNE MODULATING THERAPY TO INHIBIT TUMOR GROWTH AND METASTASES
    Publication number: 20210324103
    Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
    Type: Application
    Filed: June 29, 2021
    Publication date: October 21, 2021
    Inventors: Elizabeth E. Evans, Ernest S. Smith, Maurice Zauderer
  • Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases
    Patent number: 11078295
    Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: August 3, 2021
    Assignee: Vaccinex, Inc.
    Inventors: Elizabeth Evans, Ernest S. Smith, Maurice Zauderer
  • TREATMENT OF CANCER WITH A SEMAPHORIN-4D ANTIBODY IN COMBINATION WITH AN EPIGENETIC MODULATING AGENT
    Publication number: 20210179708
    Abstract: This disclosure provides a method for inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising administering to the subject a combination therapy comprising an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an epigenetic modulating agent, e.g., a histone deacetylase (HDAC) inhibitor (HDACi) a DNA methyltransferase (DNMT) inhibitor (DNMTi), or any combination thereof. The disclosure further provides a pharmaceutical composition comprising the combination therapy.
    Type: Application
    Filed: March 14, 2018
    Publication date: June 17, 2021
    Applicant: Vaccinex, Inc.
    Inventors: Elizabeth EVANS, Ernest SMITH, Maurice ZAUDERER
  • HUMAN ANTI-SEMAPHORIN 4D ANTIBODY
    Publication number: 20210032329
    Abstract: Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 4, 2021
    Inventors: Ernest S. SMITH, Angelica CORNELISON, Maria G.M. SCRIVENS, Mark PARIS, Maurice ZAUDERER
  • Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
    Patent number: 10800853
    Abstract: Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: October 13, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Maurice Zauderer, William J. Bowers, Alan Jonason
  • SEMAPHORIN-4D ANTAGONISTS FOR USE IN CANCER THERAPY
    Publication number: 20200317788
    Abstract: The disclosure relates to methods for treating cancer comprising determining certain patient biomarker levels prior to treatment.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 8, 2020
    Inventors: Terrence Lee Fisher, Elizabeth Evans, Maurice Zauderer
  • Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunit
    Patent number: 10662422
    Abstract: The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: May 26, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Tracy Pandina, Leslie A. Balch, Mark Paris, Maurice Zauderer, Angelica Cornelison, Renee Kirk